Jefferies analyst Brian Tanquilut maintains $Quest Diagnostics (DGX.US)$ with a buy rating, and adjusts the target price from $160 to $175.
According to TipRanks data, the analyst has a success rate of 49.5% and a total average return of 2.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The revision of the guidance for Quest Diagnostics has been attributed mainly to the integration of LifeLabs and sustained elevated utilization trends. The defensive characteristics of Quest, especially in the context of an election cycle, along with more secure estimates for the coming years, keep the outlook positive.
Quest Diagnostics delivered a strong third-quarter performance, evidenced by exceeding expectations. The company managed to maintain its earnings forecast despite the challenges posed by hurricanes, and provided an optimistic preliminary outlook for fiscal 2025.
The firm has improved its estimates following Quest Diagnostics' strong third-quarter results and encouraging initial outlook for 2025. The company's earnings visibility continues to be robust, supported by stable underlying healthcare utilization trends, gains in market share, and a favorable mix.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集團分析師Brian Tanquilut維持$奎斯特診療 (DGX.US)$買入評級，並將目標價從160美元上調至175美元。
根據TipRanks數據顯示，該分析師近一年總勝率為49.5%，總平均回報率為2.8%。
此外，綜合報道，$奎斯特診療 (DGX.US)$近期主要分析師觀點如下：
Quest Diagnostics指南的修訂主要歸因於LifeLabs的整合和利用率持續提高的趨勢。Quest的防禦特徵，尤其是在選舉週期的背景下，以及對未來幾年的更安全的估計，使前景保持樂觀。
Quest Diagnostics在第三季度表現強勁，超出預期即爲明證。儘管面臨颶風帶來的挑戰，該公司仍設法維持了其收益預期，並對2025財年提供了樂觀的初步展望。
在Quest Diagnostics公佈強勁的第三季度業績以及令人鼓舞的2025年初步展望之後，該公司提高了預期。在穩定的基礎醫療保健利用率趨勢、市場份額的增加和有利的組合的支持下，該公司的盈利知名度繼續保持強勁。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
